Dr Reddy's shall perform a full range of regulatory and commercial services to seek approval and launch Kyprolis, BLINCYTand Repatha in India
Dr Reddy's Laboratories has announced that it has entered into a strategic collaboration with Amgen to market and distribute three Amgen medicines in India in the areas of oncology and cardiology. Under the terms of the collaboration, Dr Reddy's shall perform a full range of regulatory and commercial services to seek approval and launch Kyprolis (carfilzomib), BLINCYTO(blinatumomab) and Repatha(evolocumab) in India. The collaboration leverages the capabilities of both companies, combining three of Amgen's innovative therapies with Dr. Reddy's deep understanding of patient and physician needs in India.
Dr Reddy's executive vice-president and head of India Business and global business development Mr Alok Sonig said, "We are excited about our strategic collaboration with an innovation powerhouse like Amgen and look forward to making their innovative medicines accessible to Indian patients. Addressing significant unmet needs of patients in oncology and cardiovascular are key areas in India and, therefore, a priority for us at Dr. Reddy's. We believe that good health can't wait and that this is an important milestone for us in our journey as we improve patient care."
"We are pleased to be joining forces with Dr. Reddy's Laboratories in order to make Amgen's innovative medicines available to patients in India. Dr Reddy's has significant experience serving oncology and cardiovascular patients in India and shares Amgen's interest in delivering new treatment options to seriously ill patients," said Dr Penny Wan, Amgen vice-president and general manager, Japan Asia Pacific Region.
Kyprolis was approved by the US Food and Drug Administration (US FDA) in July 2015, in combination with lenalidomide and dexamethasone, for the treatment of patients with relapsed multiple myeloma who have received one to three prior lines of therapy.
BLINCYTO is an example of immunotherapy, a treatment that uses certain parts of a person's immune system to fight diseases such as cancer. The drug is the first approved bispecific CD19-directed CD3 T-cell engager.